Track topics on Twitter Track topics that are important to you
This week, CBSA attended a stakeholder meeting on House Bill 1131, Prescription Drug Cost Education.
As the bill is currently written; it requires a drug manufacturer, wholesaler, agent or an employee of the manufacturer or wholesaler, to provide—in writing—the wholesale acquisition cost of a prescription drug to an entity or individual with whom the manufacturer, wholesaler, agent, or employee is sharing information concerning the drug. The bill also requires the drug manufacturer or wholesaler, or an agent or employee of the manufacturer or wholesaler, to provide educational materials about the acquisition costs of other prescription drugs in the same therapeutic class.
CBSA opposes HB 1131 for a number of reasons.
CBSA will continue to share our concerns on HB19-1131 with the bill’s sponsors and other key legislators. It will be heard in the House Health and Insurance Committee next Wednesday, February 20.
In addition, earlier this week the CBSA Policy Committee convened and voted to take the following positions.
CBSA will Monitor:
If you have any feedback or comment on HB19-1131 or any of CBSA’s recent positions please contact Emily Roberts, firstname.lastname@example.org.NEXT ARTICLE
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...